277 related articles for article (PubMed ID: 25128513)
1. Tocilizumab treatment increases left ventricular ejection fraction and decreases left ventricular mass index in patients with rheumatoid arthritis without cardiac symptoms: assessed using 3.0 tesla cardiac magnetic resonance imaging.
Kobayashi H; Kobayashi Y; Giles JT; Yoneyama K; Nakajima Y; Takei M
J Rheumatol; 2014 Oct; 41(10):1916-21. PubMed ID: 25128513
[TBL] [Abstract][Full Text] [Related]
2. Association of tocilizumab treatment with changes in measures of regional left ventricular function in rheumatoid arthritis, as assessed by cardiac magnetic resonance imaging.
Kobayashi Y; Kobayashi H; Giles JT; Hirano M; Nakajima Y; Takei M
Int J Rheum Dis; 2016 Nov; 19(11):1169-1174. PubMed ID: 26480957
[TBL] [Abstract][Full Text] [Related]
3. [Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis].
Avdeeva AS; Aleksandrova EN; Novikov AA; Cherkasova MV; Panasyuk EY; Nasonov EL
Ter Arkh; 2013; 85(5):24-9. PubMed ID: 23819335
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI.
Suzuki T; Horikoshi M; Sugihara M; Hirota T; Ogishima H; Umeda N; Kondo Y; Tsuboi H; Hayashi T; Chino Y; Matsumoto I; Sumida T
Mod Rheumatol; 2013 Jul; 23(4):782-7. PubMed ID: 22975733
[TBL] [Abstract][Full Text] [Related]
5. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.
Shimamoto K; Ito T; Ozaki Y; Amuro H; Tanaka A; Nishizawa T; Son Y; Inaba M; Nomura S
J Rheumatol; 2013 Jul; 40(7):1074-81. PubMed ID: 23637318
[TBL] [Abstract][Full Text] [Related]
6. Antiarrhythmic potential of anticytokine therapy in rheumatoid arthritis: tocilizumab reduces corrected QT interval by controlling systemic inflammation.
Lazzerini PE; Acampa M; Capecchi PL; Fineschi I; Selvi E; Moscadelli V; Zimbone S; Gentile D; Galeazzi M; Laghi-Pasini F
Arthritis Care Res (Hoboken); 2015 Mar; 67(3):332-9. PubMed ID: 25186226
[TBL] [Abstract][Full Text] [Related]
7. Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors.
Tanaka Y; Takeuchi T; Amano K; Saito K; Hanami K; Nawata M; Fukuyo S; Kameda H; Kaneko Y; Kurasawa T; Nagasawa H; Hoshi D; Sato E; Yamanaka H
Mod Rheumatol; 2014 May; 24(3):399-404. PubMed ID: 24252045
[TBL] [Abstract][Full Text] [Related]
8. Heart Rate-corrected QT Interval Duration in Rheumatoid Arthritis and Its Reduction with Treatment with the Interleukin 6 Inhibitor Tocilizumab.
Kobayashi H; Kobayashi Y; Yokoe I; Kitamura N; Nishiwaki A; Takei M; Giles JT
J Rheumatol; 2018 Dec; 45(12):1620-1627. PubMed ID: 30173151
[TBL] [Abstract][Full Text] [Related]
9. Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy.
Song SN; Yoshizaki K
Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):307-16. PubMed ID: 25491492
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of changes in magnetic resonance images following 24 and 52 weeks of treatment of rheumatoid arthritis with infliximab, tocilizumab, or abatacept.
Hirota T; Suzuki T; Ogishima H; Hagiwara S; Ebe H; Takahashi H; Yokosawa M; Umeda N; Kondo Y; Tsuboi H; Matsumoto I; Sumida T
Mod Rheumatol; 2016; 26(1):29-35. PubMed ID: 26140463
[TBL] [Abstract][Full Text] [Related]
11. Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium.
Ducreux J; Durez P; Galant C; Nzeusseu Toukap A; Van den Eynde B; Houssiau FA; Lauwerys BR
Arthritis Rheumatol; 2014 Jan; 66(1):15-23. PubMed ID: 24449571
[TBL] [Abstract][Full Text] [Related]
12. Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial.
Kume K; Amano K; Yamada S; Hatta K; Ohta H; Kuwaba N
J Rheumatol; 2011 Oct; 38(10):2169-71. PubMed ID: 21807781
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of tocilizumab on MRI-determined bone oedema in rheumatoid arthritis.
Bensaoud N; Rostom S; Bahiri R; Hajjaj-Hassouni N
Clin Rheumatol; 2015 Jun; 34(6):1031-7. PubMed ID: 25903819
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab: retreatment of patients with rheumatoid arthritis with novel anti-IL-6 receptor antibody after a long-term interval following SAMURAI: the RONIN study.
Sagawa A
Mod Rheumatol; 2011 Aug; 21(4):352-8. PubMed ID: 21347804
[TBL] [Abstract][Full Text] [Related]
15. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52.
Izumi K; Kaneko Y; Yasuoka H; Seta N; Kameda H; Kuwana M; Takeuchi T
Mod Rheumatol; 2015 Jan; 25(1):31-7. PubMed ID: 24684408
[TBL] [Abstract][Full Text] [Related]
16. The effect of tocilizumab on bone mineral density in patients with methotrexate-resistant active rheumatoid arthritis.
Kume K; Amano K; Yamada S; Kanazawa T; Ohta H; Hatta K; Amano K; Kuwaba N
Rheumatology (Oxford); 2014 May; 53(5):900-3. PubMed ID: 24441151
[TBL] [Abstract][Full Text] [Related]
17. Response to tocilizumab in rheumatoid arthritis is not influenced by the body mass index of the patient.
Pers YM; Godfrin-Valnet M; Lambert J; Fortunet C; Constant E; Mura T; Pallot-Prades B; Jorgensen C; Maillefert JF; Marotte H; Wendling D; Gaudin P
J Rheumatol; 2015 Apr; 42(4):580-4. PubMed ID: 25641885
[TBL] [Abstract][Full Text] [Related]
18. Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein-Enriched Serum in Rheumatoid Arthritis.
Ormseth MJ; Yancey PG; Solus JF; Bridges SL; Curtis JR; Linton MF; Fazio S; Davies SS; Roberts LJ; Vickers KC; Kon V; Michael Stein C;
Arthritis Rheumatol; 2016 Sep; 68(9):2099-105. PubMed ID: 26991245
[TBL] [Abstract][Full Text] [Related]
19. Very early improvements in the wrist and hand assessed by power Doppler sonography predicting later favorable responses in tocilizumab-treated patients with rheumatoid arthritis.
Kume K; Amano K; Yamada S; Hatta K; Kuwaba N; Ohta H
Arthritis Care Res (Hoboken); 2011 Oct; 63(10):1477-81. PubMed ID: 21702090
[TBL] [Abstract][Full Text] [Related]
20. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
Stubenrauch K; Wessels U; Birnboeck H; Ramirez F; Jahreis A; Schleypen J
Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
